In a long-term phase 3 study of esaxerenone in patients with essential hypertension, NT-proBNP levels tended to decrease over the 52-week treatment period; [26] however, to the best of our knowledge, no further studies have verified the effect of esaxerenone on NT-proBNP. The gene discussed is NPPB; the disease is hypertensive disorder.